Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

SAN FRANCISCO, CA USA (UroToday.com) - Dr. Vincent Launay-Vacher presented results from the MARS (Management of Antiangiogenics Renovascular Safety) study, a prospective multi-center study of renovascular tolerance of anti-VEGF drugs (AVD) in multiple different tumor types.

The authors’ goal was to assess the prevalence of renovascular abnormalities before treatment with anti-angiogenic drugs. The incidence of hypertension (HTN) and proteinuria (PU) were assessed both prior to initiation of anti-angiogenic therapy and following treatment. Patients included were naïve of any previous AVD, and had standard indications for treatment with AVD. Demographic, oncological, and renovascular data were collected and compared.

gucancerssympalt thumbIn total, 1 124 patients were studied; 137 had RCC, and 112 were treated with sunitinib. Median age was 61 years, and visceral, bone, and brain metastases were present in 71%, 42%, and 12.5% of patients, respectively. Sunitinib was administered at usual doses. Treatment duration was > 6 or > 12 months in 70.5% and 50.8%, respectively. At baseline, HTN and PU were present in 43.8% (grade 3 in 4.5%) and 15.6%, respectively. During follow-up after treatment with sunitinib, 75.0% developed PU (4.5% grade 3), and 21.4% developed HTN (14.3% grade 3). Overall, no thrombotic micro-angiopathy was reported, indicating it remains a rare side effect of anti-VEGF therapy.

The prevalence of renovascular abnormalities in patients with mRCC prior and following initiation of sunitinib is high. Thorough evaluation of renovascular status should be performed in all patients prior to initiation of AVD therapy. Follow-up of renovascular status should be performed in all patients.

Highlights of a presentation by Vincent Launay-Vacher, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Pitie-Salpetriere Hospital, Paris France

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Calendar
Upcoming urology industry events
February 26-27, 2018 / The Royal Marsden Hospital
MediSens – The European Medical Imaging Conference
February 27-March 3, 2018 /
SUFU 2018 Winter Meeting
March 1-3, 2018 / Omni Amelia Island Plantation Resort, Fernandina Beach, FL
75th Annual Meeting Mid-Atlantic Section of the American Urological Association
March 1-3, 2018 / Marriott St. Louis Airport, St. Louis, Missouri
2018 Bladder Cancer Academy
March 3, 2018 / DoubleTree by Hilton Hotel Dallas - Campbell Centre
Advances in Cancer Immunotherapy™ - Dallas, TX
Journals
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday